Prof. Fruchart said: ‘We are delighted by this award, which recognises the impact of this consensus statement. This is another milestone on the journey for the SPPARMα paradigm, culminating in the PROMINENT trial.’ Read the award winning article here ➡️ h
4,393 followers
2,224 followers
「フィブラート系」ではなく「SPPARMα(スパームアルファ)」 選択的ペルオキシソーム増殖因子活性化受容体アルファモジュレーター(SPPARMα)パラダイム:概念的枠組みと治療の可能性 https://t.co/briIPZa4D2 https://t.co/xFJ2fA1o89
4,393 followers
Over 50 internationally renowned clinical and scientific experts came together to discuss the SPPARMα concept and its therapeutic potential for addressing residual vascular risk. Click the link below to read this essential guide for clinicians: https://t.
159 followers
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initi…